drugset / Trial / NCT07497399
Targeting Agonists of Glucagon-like Peptide-1 Receptor for Multiple Sclerosis
Phase 2
Recruiting
120 enrolled
Johns Hopkins University
National Multiple Sclerosis Society · collabRace to Erase MS · collab
RandomizedParallel-groupQuadruple-blindTreatment
Summary
The goal of this clinical trial is to evaluate if the study drug will reduce brain and retinal atrophy by reducing inflammation and subsequently slowing neurodegeneration in people with Multiple Sclerosis. The main outcome for the trial is change in normalized brain parenchymal volume (nBPV), measured by magnetic resonance imaging (MRI). Researchers will compare outcomes from participants randomized to the study drug, versus participants randomized to placebo, to see if there are signs of slowed neurodegeneration (i.e., reduction in brain and retinal atrophy).
Timeline
- Start
- 2026-04-28
- Primary completion
- 2030-01
- Completion
- 2030-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | NLY01 | Peptide | 10 mg | Subcutaneous |